{"filing":{"accession_number":"0001193125-26-396646","cik":"0002088082","ticker":null,"company_name":"Electra Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"d185250d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2088082/000119312526396646/d185250d8k.htm"},"events":[{"id":33961,"run_id":31264,"accession_number":"0001193125-26-396646","anchor_item_number":"8.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Electra Therapeutics completed its initial public offering on September 21, 2026, issuing 23,333,334 shares at $15.00 per share and generating approximately $350.0 million in gross proceeds.","company_name":"Electra Therapeutics, Inc.","ticker":null,"filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37563,"accession_number":"0001193125-26-396646","item_number":"8.01","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The disclosure reports the closing of an IPO with 23,333,334 shares at $15.00 per share, generating approximately $350.0 million in gross proceeds. This is a material capital-raising event that fundamentally changes the registrant's capitalization and public status. While IPO closings are significant financial events, they do not fit neatly into the specific taxonomy categories (debt_issuance, dilutive_issuance, dividend_distribution, etc.); dilutive_issuance typically applies to private placements or unregistered offerings, not registered public offerings. Financial_other is the most appropriate classification for this material but domain-specific financial event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:03:17.319143+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":33962,"run_id":31264,"accession_number":"0001193125-26-396646","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"The Company adopted routine amendments to its certificate of incorporation and bylaws effective upon IPO closing, which are standard administrative governance documents previously approved by the board and stockholders.","company_name":"Electra Therapeutics, Inc.","ticker":null,"filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37562,"accession_number":"0001193125-26-396646","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns routine amendments to the Company's certificate of incorporation and bylaws effective upon IPO closing on September 21, 2026. While governance-related, these are standard administrative documents adopted in connection with going public and previously approved by the board and stockholders. The filing references the prospectus for substantive details, indicating these are boilerplate IPO-related governance changes rather than material governance events that would affect investor assessment beyond the IPO itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:03:17.319143+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37562,"accession_number":"0001193125-26-396646","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns routine amendments to the Company's certificate of incorporation and bylaws effective upon IPO closing on September 21, 2026. While governance-related, these are standard administrative documents adopted in connection with going public and previously approved by the board and stockholders. The filing references the prospectus for substantive details, indicating these are boilerplate IPO-related governance changes rather than material governance events that would affect investor assessment beyond the IPO itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:03:17.319143+00:00","company_name":"Electra Therapeutics, Inc.","ticker":null,"filing_date":"2026-09-21"},{"id":37563,"accession_number":"0001193125-26-396646","item_number":"8.01","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The disclosure reports the closing of an IPO with 23,333,334 shares at $15.00 per share, generating approximately $350.0 million in gross proceeds. This is a material capital-raising event that fundamentally changes the registrant's capitalization and public status. While IPO closings are significant financial events, they do not fit neatly into the specific taxonomy categories (debt_issuance, dilutive_issuance, dividend_distribution, etc.); dilutive_issuance typically applies to private placements or unregistered offerings, not registered public offerings. Financial_other is the most appropriate classification for this material but domain-specific financial event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:03:17.319143+00:00","company_name":"Electra Therapeutics, Inc.","ticker":null,"filing_date":"2026-09-21"}]}